Clinical trials: sponsored by Merck Sharp & Dohme LLC
Healthy
A Clinical Trial of MK-4082 in Healthy Participants (MK-4082-005)
Researchers are looking for new weight loss medicines for people with higher body weight. The trial medicine, MK-4082, is different from similar weight loss medicines because people take it as a pill instead of an injection.
- Trial name
- NCT07697625
- Testing
- MK-4082, Diltiazem, Rescue medication
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Study of MK-7240 in Healthy Participants (MK-7240-009)
The goal of this study is to learn what happens to MK-7240 in a healthy person's body over time (pharmacokinetic or PK study). Researchers also want to learn about the safety of MK-7240 and if people tolerate it.
- Trial name
- NCT07405177
- Testing
- Tulisokibart Form 1, Tulisokibart Form 2
- Where
- 2 sites in Australia
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).
Epstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis.
- Trial name
- NCT06655324
- Testing
- V350A, V350B
- Where
- 9 sites in United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis, Healthy
A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001)
The purpose of this trial is to learn about a trial medicine called MK-8644. This trial is the first time researchers will give MK-8644 to people.
- Trial name
- NCT07850310
- Testing
- MK-8644
- Where
- Australia
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-1)
The purpose of this study is to demonstrate that V181 is safe and well tolerated, elicits an immune response, and reduces the frequency of virologically confirmed dengue (VCD) of any severity, due to any of the 4 dengue…
- Trial name
- NCT07013487
- Testing
- V181
- Where
- 41 sites in Indonesia, Malaysia and 5 more
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008)
The purpose of this trial is to compare what happens to MK-1406 in the body of healthy participants when it is given as 2-injections and 3-injections.
- Trial name
- NCT07743151
- Testing
- MK-1406
- Where
- 7 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Study of V118E in Healthy Participants (V118E-003)
Researchers are looking for new vaccines to prevent illnesses caused by a type of bacteria called Streptococcus pneumoniae. There are many different types of Streptococcus pneumoniae bacteria, called serotypes.
- Trial name
- NCT07168915
- Testing
- V118E, PREVNAR 20™, Saline
- Where
- 4 sites in United States
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Papillomavirus Infections
A Clinical Study of V503 in Chinese Females Who Have Previously Received a Bivalent Human Papillomavirus (HPV) Vaccine (V503-108)
Researchers want to learn if V503 (also called the 9-valent human papillomavirus [9vHPV] vaccine, recombinant) can induce an immune response to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Chinese females who previously…
- Trial name
- NCT07785843
- Testing
- V503
- Where
- China
- Volunteers
- 930 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Papillomavirus Infections
Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)
The purpose of this study is to evaluate the efficacy, immunogenicity and safety of the 9vHPV vaccine in men 20 to 45 years of age.
- Trial name
- NCT04199689
- Testing
- 9vHPV Vaccine
- Where
- 103 sites in United States, Belgium and 14 more
- Volunteers
- 6,033 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Study of V132 in Healthy Older Participants (V132-001)
The goal of this study is to learn about the safety and immune response to the V132 vaccine in healthy older adults.
- Trial name
- NCT07712575
- Testing
- V132 Formulation 1, V132 Formulation 2, V132 Formulation 3
- Where
- 10 sites in United States
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy, Renal Impairment
A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)
Researchers have designed a new study medicine called enlicitide decanoate as a new way to lower the amount of low-density lipoprotein cholesterol (LDL-C) in a person's blood.
- Trial name
- NCT06643377
- Testing
- Enlicitide
- Where
- 5 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)
Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection. The goals of this study are to learn: If taking MK-8527 once a month works to prevent HIV-1 infection better than a…
- Trial name
- NCT07071623
- Testing
- MK-8527, Emtricitabine/tenofovir disoproxil (FTC/TDF)
- Where
- 30 sites in Kenya, South Africa and 1 more
- Volunteers
- 4,580 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Clinical Trial of MK-1403 in Healthy Participants (MK-1403-007)
The purpose of this trial is to learn about a trial medicine called MK-1403. Researchers designed MK-1403 to treat a type of heart and blood vessel disease called atherosclerotic cardiovascular disease (ASCVD).
- Trial name
- NCT07677163
- Testing
- MK-1403 formulation (FM) 1 + additive, MK-1403 FM2 + additive
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).
Researchers are looking for new ways to prevent cancers related to human papillomavirus (HPV). HPV is a common virus that can cause an infection. There are many different types of HPV.
- Trial name
- NCT06623409
- Testing
- GARDASIL®9 (G9), V540B
- Where
- 4 sites in United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Clinical Trial of MK-6916 With Midazolam and Rosuvastatin in Healthy Participants (MK-6916-012)
Researchers are looking for new treatments for pain. The goal of this trial is to learn if MK-6916 changes what happens to the midazolam and rosuvastatin in healthy participants' bodies.
- Trial name
- NCT07862621
- Testing
- Midazolam, Rosuvastatin, MK-6916
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV-1 Infection
DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)
This is a randomized, active-controlled, double-blind clinical study designed to evaluate the antiretroviral activity, safety, and tolerability of doravirine/islatravir (DOR/ISL [MK-8591A]) in treatment-naïve participants with…
- Trial name
- NCT05705349
- Testing
- DOR/ISL, BIC/FTC/TAF
- Where
- 131 sites in United States, Argentina and 19 more
- Volunteers
- 537 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Clinical Trial to Evaluate the Effects of MK-4646 on Rosuvastatin in Healthy Participants (MK-4646-007)
Researchers are looking for new treatments for people living with HIV-1 (Human Immunodeficiency Virus Type 1). HIV-1 is the most common type of HIV, which is a virus that attacks cells of the immune system.
- Trial name
- NCT07785830
- Testing
- Rosuvastatin, MK-4646
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Lower Respiratory Tract Infection
A Clinical Trial of V175 and V175A in Healthy Adults
Researchers are looking for new vaccines to prevent lower respiratory tract infections. A lower respiratory tract infection is an infection in the lower part of the airways and/or the lungs.
- Trial name
- NCT07855510
- Testing
- V175, V175A, Control Vaccine
- Volunteers
- 564 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumococcal Infection
A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
Researchers are looking for new vaccines to prevent pneumococcal disease, which is any infection in the lungs or other parts of the body that is caused by a type of bacteria called Streptococcus pneumoniae.
- Trial name
- NCT07300267
- Testing
- V118C (Stage 1), V118C (Stage 2), PCV20 (Stage 1)
- Where
- 15 sites in United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV
A Clinical Study of Alimatravir (MK-8527) in Transgender (Trans) and Gender Diverse Individuals on Gender-affirming Hormone Therapy and at Low Likelihood of Human Immunodeficiency Virus (HIV)-1 Exposure (MK-8527-018)
The goal of this study is to learn about the safety of alimatravir (MK-8527) in transgender and gender-diverse people and if they tolerate it.
- Trial name
- EXPrESSIVE-18 (NCT07850609)
- Testing
- Alimatravir
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC